SLC6A3 and Parkinson disease: Neuroimaging is only used as an assistance in PD diagnosis, although the clinical utility of neuroimaging such as SPECT (single photon emission computed tomography) is high and results of dopamine transporter scan (DaTscan) lead to modified diagnosis in one-third of the patients4; (2) Currently, there are few reliable biomarkers for PD5, in particular, there is no in vivo imaging tool available to directly image the accumulation of α–synuclein aggregates or the spreading of Lewy bodies in the brain of a PD patient6.